转自：美迪西Medicilon
Swipe left for English
美迪西是一家专业的生物医药临床前综合研发服务CRO，为全球的医药企业和科研机构提供全方位的符合国内及国际申报标准的一站式新药临床前研发服务。20多年深耕生物医药临床前研发领域，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有520件IND获批临床。
近年来，美迪西搭建了核酸、ADC、PROTAC、抗体、多肽、疫苗以及细胞与基因治疗等新分子药物研发服务平台，并积累了丰富的成功案例。葛建博士的加入，将推动美迪西临床前研发技术服务平台持续创新发展，进一步增强提供国际标准服务的核心竞争力。
2025年4月，上海美迪西生物医药股份有限公司（股票代码：688202.SH）任命葛建博士为临床前研究事业部执行副总裁。葛博士将重点优化和加强创新药物临床前研究能力，提高对国内国际客户的服务水平，充分满足各类客户需求。尤其注重新靶点，新作用机制，新技术的研究与拓展，密切关注FDA法规要求，及时跟进布局，和我们广大合作者一起，将创新药研发水平不断提高。
葛建 博士
美迪西临床前研究事业部执行副总裁
葛建，中国药科大学学士，英国Bradford大学博士，国家级海外高层次人才，华中科技大学特聘教授、武汉理工大学讲座教授，担任中国神经精神药理学会理事、中国药理学会麻醉药理学专业委员会理事、中国科技部重大专项评审专家等职务。
葛博士拥有30余年创新药物研发及临床研究经验，不仅构筑起深厚的研发技术体系，更在实战管理中积累了丰富经验，尤其在神经精神、心脑血管、代谢类疾病、自身免疫以及肿瘤药物研发领域成果斐然，精通新药NMPA/FDA、IND及NDA申报法规和流程。
在加入美迪西之前，葛博士已在国际顶尖学术机构与制药企业积累了丰富经验。他于英国Bradford大学获药理学博士学位后，任职于英国Birmingham大学、Bristol大学，以及美国先灵葆雅制药英国研发中心，在国际各大期刊发表各类学术论文70余篇，荣获发明专利30余项。此后，葛博士深度参与本土创新药产业升级，在恒瑞医药、启瑞药业、华汇拓医药等担心高管，曾主导开发了抗阿尔海默兹药物、抗肿瘤药物、抗抑郁新药、骨关节炎药物等创新药管线，并成功完成多项中美双报IND及NDA申请，累计推动超30项创新药物研究和开发。
葛建 博士
美迪西临床前研究事业部执行副总裁
“美迪西在药物临床前研发领域的前瞻布局令人印象深刻，特别是在核酸、ADC、PROTAC、抗体、细胞与基因治疗等新分子药物研发领域构建了兼具国际标准与本土效率优势的研发体系。我非常荣幸加入美迪西，期待与团队通力协作，推动更多创新疗法经美迪西赋能走上临床。”
陈春麟 博士
美迪西创始人、董事长&CEO
“葛建博士在神经精神、心脑血管、代谢类疾病以及肿瘤疾病肿瘤等领域的深厚积累，与美迪西的技术服务平台高度协同。他在创新药研发、国际标准申报及复杂项目管理上的卓越能力，将助力美迪西为全球客户提供更具竞争力的创新药临床前研究方案。”
关于美迪西
美迪西（股票代码：688202.SH）成立于2004年，总部位于上海，致力于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研究服务。美迪西的一站式综合服务以强有力的项目管理和更高效、高性价比的研发服务助力客户加速新药研发进程，服务涵盖医药临床前新药研究的全过程，包括药物发现、药学研究及临床前研究。至2024年底，美迪西已为全球超2000家客户提供药物研发服务，参与研发完成的新药及仿制药项目已有520件IND获批临床，与国内外优质客户共同成长。美迪西将继续立足全球视野，聚力中国创新，为人类健康贡献力量！
右滑查看中文版
Medicilon, a leading pharmaceutical preclinical CRO, announced the appointment of Dr. Jian Ge as Executive Vice President of the Preclinical Research Division. Dr. Ge will focus on optimizing preclinical research capabilities for innovative drugs, and significantly enhancing services for global clients. He will also emphasize research into new targets, new mechanisms, and technologies, while closely monitoring FDA regulatory requirements. Together with partners, he aims to continuously increase the standards of innovative drug R&D.
Dr.Jian Ge
EVP of Preclinical Research Division of Medicilon
Dr. Jian Ge holds a Ph.D. in Neuroscience from the University of Bradford, UK, and a Bachelor’s degree in Pharmacology from the China Pharmaceutical University. He is recognized as a national high-level talent and has served as a professor at Huazhong University of Science and Technology and Wuhan University of Technology. Dr. Ge is also a board member of the Chinese Society of Neuropsychopharmacology and the Anesthesiology Pharmacology Committee of the Chinese Pharmacological Society. He also serves as a review expert for China’s National Major Science and Technology Projects.
Dr. Ge has gained over 30 years experience in drug discovery, with significant achievements in CNS, cardiovascular, metabolic, autoimmune, and oncology diseases. He is proficient in the NMPA/FDA regulatory requirements for IND and NDA applications.
Before joining Medicilon, Dr. Ge worked at top global academic institutions and pharmaceutical companies, including the University of Birmingham, the University of Bristol, and Schering-Plough’s UK R&D Center. He has published over 70 academic papers and holds more than 30 patents. He has also led the drug discovery teams at companies such as Hengrui Pharma, Qirui Pharma, and Zhejiang Huahai Pharma, successfully completing multiple IND and NDA applications for both the US and China and advancing over 30 innovative drug projects.
In recent years, Medicilon has expanded its capabilities in new molecular drug development, such as nucleic acids, ADCs, PROTACs, antibodies, peptides, vaccines, and cell and gene therapies. Dr. Ge’s appointment aims to drive continuous innovation and enhance Medicilon’s core competitiveness in providing international-standard services.
Dr. Lilly Xu
EVP of Preclinical Research Division of Medicilon
“Medicilon’s forward-looking approach in preclinical drug R&D is impressive, especially in nucleic acids, ADCs, PROTACs and antibodies. I am honored to join Medicilon and looking forward to working with the team to empower more innovative therapies to move into clinical trials.”
Dr. Chunlin Chen
Founder, Chairman and CEO of Medicilon
“Dr. Ge’s deep expertise in CNS, cardiovascular, metabolic, and oncology drug development is highly synergistic with Medicilon’s technology platform. His outstanding capabilities in innovative drug R&D and international standards will strengthen our ability to deliver competitive preclinical solutions worldwide.”
About Medicilon
From its inception in 2004, Shanghai Medicilon Inc. (stock code: 688202.SH) has been committed to providing comprehensive R&D services to pharmaceutical companies, research institutions, and any organizations working in the preclinical space. By the end of 2024, Medicilon has provided drug development services to over 2,000 clients worldwide, and has been involved in the research and development of 520 new drugs and generic drug projects that have been approved for clinical trials with IND applications.
（转自：美迪西Medicilon）
